ERBB2 and non-small cell lung carcinoma: HER2 is overexpressed in 10–20% of NSCLC cases and in perhaps as many as 30% of lung adenocarcinomas [19,20,21,22,23], where overexpression is associated with adverse tumor characteristics and poor patient prognosis [24,25].